ClinicalTrials.gg
Active, not recruitingNCT05908643Updated Oct 28, 2026

A First-In-Human Trial of pTTL in Advanced Colorectal Cancer

A Phase 1/2 interventional study of pTTL in Colorectal Cancer, sponsored by Neogap Therapeutics AB. Active, not recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Neogap Therapeutics AB · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 28, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Colorectal Neoplasms with a site in Sweden — 27 open to participants now, 38 under way, 10 of them phase 3. Colorectal Neoplasms · Sweden.

Planned enrollment
85th of 89
16 · median 215
Started
2023
with 7 others
Phase 1/2
15 of 124
2 open now
Primary completion
2030-12
later than 35 of 37 live
Registered
101st of 124
by date

Among the 124 studies in Colorectal Neoplasms with a site in Sweden, this one is the 85th largest by planned enrollment of the 89 interventional ones that give a count, is one of 8 that started in 2023, is one of 15 in phase 1/2, reaches primary completion later than 35 of the 37 other live ones, and was the 101st registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

27 of the 124 studies in Colorectal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Colorectal Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

This is an open-label, non-randomised FIH trial investigating the safety and tolerability of a novel ATMP, pTTL, composed of autologous tumour-draining lymph node-derived T cells stimulated in vitro with personalised cancer neoantigens.

The neoantigens are selected through a process starting with next generation sequencing (NGS) of tumour material from the patient followed by selection of neoantigenic mutations using an in-house software, PIOR®. Selected neoantigen epitopes are expressed as recombinant proteins, NAG, and used to stimulate T cells to promote neoantigen-specific T cell expansion in vitro in pTTL production.

pTTL is thus based on autologous cells stimulated with patient-specific neoantigens. In consequence, every pTTL product is unique and designated for use in one single individual.

pTTL will be administered to patients with stage IV colorectal cancer (CRC) as a single intravenous dose.

Read the detailed description

STUDY RATIONALE The present trial is an open-label, non-randomised FIH trial investigating the safety and tolerability of pTTL, an immunotherapy consisting of autologous T cells activated and expanded in vitro using tumour-specific personalised neoantigens. The scientific rationale for pTTL relies on the fact that somatic mutations in tumour cells arising during malignant transformation result in altered proteins or peptides, so called neoantigens. Each individual tumour harbours multiple mutations that form a unique mutation profile, which enables personalisation of each therapeutic product. The neoantigens distinguish tumour cells from normal cells and make the tumour cells targetable by the immune system, and also allows targeting of several targets in the tumour simultaneously. In the present trial, up to 36 neoantigens will be targeted.

The starting material for pTTL is derived from tumour-draining regional lymph nodes (RLNs). The choice of this source of T cells is based on several advantages: The exposure to tumour antigens and, in the case of metastasis, tumour cells causes an enrichment of tumour- specific T cells. These T cells also have the potential to be superior to tumour-infiltrating T cells due to less exposure to tumour-mediated immunosuppression.

The production process for pTTL includes in vitro expansion, which increases the neoantigen-reactive T cell population. The selective T cell expansion is achieved by stimulation with protein constructs containing neoantigen epitopes, based on sequencing data from each patient's own tumour. This improves the chance of effective cancer cell eradication by both increasing the number of cells able to recognise and respond to the tumour, and by breaking immunological tolerance created in vivo by immunosuppressive mechanisms through activation in a non-suppressive environment.

PATIENTS The selected target group of the trial is adults with stage IV CRC. Patients may be considered eligible for inclusion if they have received treatments according to standard of care or if further standard of care treatment options are judged not to be in the patients' best interest (e.g. due to toxicity issues). Patients could also be eligible for inclusion in the trial during a scheduled pause in ongoing palliative therapy, at the discretion of the treating Investigator. Eligible patients must have a primary or metastatic lesion that is accessible to biopsy or surgery to obtain tumour material for NGS analysis. In addition, it is a requirement that the patient can undergo surgical excision of RLNs for use in pTTL production. Eligible patients should also have a good performance status (ECOG 0-1) and organ function, and no pre-existing conditionings deemed to increase their risk for severe side effects of pTTL therapy. Materials for Part I of the trial can be collected, while non-curative therapeutic options remain, and cryopreserved for later use if the patient should become eligible for inclusion in Part II.

METHODOLOGY The trial is composed of 3 parts, referred to as Part I, Part II and Part III.

Patients will be consented separately for Part I and for Part II/III: a first consent is given for tissue collection and pTTL production, and a second consent is given for pTTL treatment, including pre-conditioning chemotherapy and follow-up.

Part I of the trial entails patient identification, recruitment and screening of trial patients. It also comprises production of pTTL, which is performed in 3 steps:

  1. Collection of tumour samples and normal samples for NGS and neoantigen selection. Production of stimulatory NAG-coupled beads raw material TC0301.
  2. Collection of starting material for pTTL manufacturing from RLN.
  3. pTTL manufacturing.

The time required from collection of tumour material and RLNs up until pTTL production and administration to the patient is approximately 8 to 12 weeks. The RLN starting material is cryopreserved after initial processing, enabling flexibility in the timing of pTTL administration.

Part II of the trial entails pre-conditioning and supportive care therapy, treatment with pTTL, and 26 weeks safety follow-up.

Pre-conditioning contains cyclophosphamide and fludarabine, and will be administered between Day -7 and Day -5 before scheduled pTTL administration. Supportive care treatment will start on Day -9 or Day -8. pTTL administration will normally be administered on Day 1, with the option of administration on Day -3 if cell expansion kinetics during pTTL production indicates this would be preferable. Part II will end when the last treated patient has been followed for 26 weeks or earlier in case of death or patient withdrawal.

Part III of the trial is a long-term follow-up initiated after completion of the initial 26 weeks safety follow-up period. Patients will participate in Part III for up to 4.5 years after end of Part II or until death, whichever comes first.

pTTL DOSAGE AND ADMINISTRATION The drug product (DP), i.e. pTTL, is composed of in vitro expanded RLN cells, enriched for neoantigen-specific T cells. It is formulated as a cell suspension with the excipients NaCl (9 mg/mL) and human serum albumin (25 mg/mL) in a transfusion bag intended for intravenous transfusion. The product is administered fresh. Each patient will receive a single administration of pTTL.The cell dose obtained during the manufacturing process will vary depending on the size of the neoantigen-reactive clones present in the starting material and their proliferative capacity. The minimum dose of a pTTL unit is 20 million viable cells and the maximum dose is 1 billion viable cells.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Immunotherapy
  • Adoptive cell therapy
  • T cell therapy
  • Neoantigens
  • Autologous cell therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Adult (age ≥18 years).
  3. Histological or cytological confirmation of CRC.
  4. Verified disease (stage IV classification) and have received all possible standard of care therapies, OR further standard of care therapies are currently not considered to be in the patient's best interest, OR toxicity from previous therapy limits the choice of suitable standard of care therapy OR scheduled pause in palliative standard of care therapy as judged by the Investigator.
  5. according to RECIST1.1.
  6. Minimum of 6 months at primary inclusion and 3 months at pTTL administration.
  7. Minimum life expectancy of 3 months from the time that the individual pTTL DP is estimated to be available (as per Investigators clinical assessment). 7. performance status 0 to 1
  8. Adequate hematopoietic, hepatic and renal function defined as:

    1. ≥ 95 g/L (blood transfusion not less than 21 days prior to screening),
    2. ≥ 1.0x 109/L, ≥100 x 109/L
    3. Total \< 1.5 x (does not apply to patients with Gilberts Syndrome)
    4. and ALT ≤ 1.5 x ULN (or ≤ 5 x ULN in the presence of liver metastases)
    5. Serum creatinine ≤ ULN (if serum creatinine is between 1 and 1.5 x ULN, patients may be eligible provided that the calculated is at least 35 mL/min using method).
    6. Albumin ≥24 g/L
  9. Patients of or their partners of childbearing potential must be willing to take the appropriate precaution to avoid pregnancy or fathering a child for the duration of Part I and Part II and practice an approved, highly effective method of during treatment and for 6months after receiving pTTL.

    Approved methods of birth control include:

    • Combined (oestrogen and progesterone containing) hormonal birth control associated with inhibition of ovulation: oral, intravaginal, transdermal
    • Progesterone-only hormonal birth control associated with inhibition ofovulation: oral, injectable, implantable
    • Intrauterine device (IUD)or intrauterine hormone-releasing system (IUS)•Bilateral tubal occlusion
    • Vasectomised partner
    • True sexual abstinence when this is in line with the preferred and usuallifestyle of the patient. Periodic abstinence (e.g., calendar ovulation,symptothermal, post-ovulation methods) is not acceptable
  10. Able to undergo surgery or to obtain tumour tissue for neoantigen evaluation and to retrieve RLNs as starting material for pTTL manufacturing
  11. The area from which the RLNs will be obtained shall not have been exposed to radiotherapy.

Exclusion criteria

Exclusion Criteria:

  1. Less than 4 months at primary inclusion and 6 months at pTTL administration since a cardiovascular event such as myocardial infarction, unstable angina, angioplasty, bypass surgery, stroke or (TIA). Atrial fibrillation if treated and well controlled is not considered a bar to inclusion even if diagnosed less than 6 months ago.
  2. Congestive heart failure (NYHA)class III or IV.
  3. Significantly reduced lung function with clinical implications. If such is suspected, spirometry should be performed. Spirometry should also be considered in patients who have been hospitalised due to Covid-19 infection during the last 6 months, and in patients with any other lung affectation judged significant by the Principal Investigators, in discussion withSponsor's Medical Representative, such as treatment-related pneumonitis or severe lung infection. Spirometry results of less than 65% of the expected value regarding (FEV1) and/or diffusion capacity (diffusing capacity of the lung for carbon monoxide, DLCO,corrected for haemoglobinvalue, DLCOco) is regarded as a criterium for exclusion.
  4. Any severe acute or chronic medical condition that places the patient at increased risk or interferes with the interpretationof trial results (as judged by the Principal Investigators, in agreement with Sponsor's Medical Representative).
  5. Immunodeficiency disorders which may pose a risk for patients treated with pTTL, and/or affect the outcome of the pTTL treatment, as judged by Investigator at the Treatment Site and/or the Investigator at the Recruitment and Follow-Up Site Immunodeficiency disorders are here defined as including inborn and acquired disorders reducing immunity but excluding (HIV), which is discussed below. Examples include common variable immunodeficiency and status post transplantation of a solid organ or stem cells. Immunodeficiency caused by the cancer disorder to be treated within the trial or such cancer treatments as have already been administered is considered a separate entity. This, if severe, might impact the production of pTTL and potentially also the treatment outcome, and needs to be carefully assessed as regards patient and pTTL production risks before inclusion.
  6. Autoimmunity disorders which may pose a risk for patients treated with pTTL, and/or affect the outcome of the pTTL treatment, as judged by Investigator at the Treatment Site and/or the Investigator at the Recruitment and Follow-Up Site.
  7. (patient with previously treated are eligible if there is no evidence of disease progression for a minimum of 8 weeks prior to inclusion

    • in these cases a CNS MRI is required within the screening period. These patients must not have symptoms from their brain metastases or treatment thereof and must not be taking medications for treatment of CNS symptoms).
  8. Patients are not allowed to have ongoing systemic concomitant medications. Systemic immunosuppressive treatments should be completed 2 weeks prior to surgery and/or 2 weeks prior to dose. Steroid medications are allowed if they are used as substitution or are administrated topically or as inhalation steroids for asthma.
  9. Previous Grade 3 or greater immune-related toxicity from checkpoint modulation or other immunotherapy (unless the toxicity has resolved and the patient rechallenged with the therapy without recurrence of toxicity, in which situation the patient can be considered).
  10. Acute or chronic infection with or C or syphilis.
  11. HIV infection.
  12. Pregnancy or breast-feeding.
  13. Investigator considers the patient unlikely to comply with trial procedures, restrictions and requirements.
  14. For patients required to undergo trial-specific surgery to obtain starting material:

    1. Less than 3 identifiable enlarged lymph nodes on pre-surgery radiology accessible for surgical excision.
    2. Previous surgical removal of the primary CRC tumour (would entail a high risk surgery)
    3. Unable to withstand the planned surgery (including ineligibility for general anaesthesia)

    At decision to proceed to pTTL administration:

  15. Less than 4 weeks since stopping previous systemic cancer treatment.
  16. Less than 2 weeks since stopping radiotherapy.
  17. Less than 4 weeks after major surgery and less than 3 weeks after minor surgery.
  18. Participation in any other clinical cancer therapy trial, and planned treatment or treatment with another drug, within the previous 4 weeks.
  19. Less than 4 weeks since administration of .
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Treatment with pTTL

    A single dose of pTTL will be administered after pre-conditioning chemotherapy with Fludarabine (30 mg/m(2) body surface area) x 3 and Cyclophosphamide (300 mg/m(2) body surface area) x 3 on days -7 to -5. pTTL will usually be infused on day 1 (5 days after last chemotherapy) with the option of administering it on day -3 if judged preferable based on the T cell expansion kinetics during pTTL production. pTTL is administered as a fresh product directly after production. Dose escalation will be applied. Cohort 1 (1 patient): 1 million (with an accepted range of down to -5%) viable cells per kg body weight Cohort 2 (3 patients): 2.5 million (down to -5%) viable cells per kg body weight Cohort 3 (3 patients): 5 million (down to -5%) viable cells per kg body weight Cohort 4 (remaining patients): up to 1 billion viable cells

    Drug: pTTL

Interventions

  • DrugpTTL

    pTTL is an autologous cell product for adoptive cancer immunotherapy containing in vitro expanded T cells stimulated with patient-specific tumour neoantigens derived from tumour-draining lymph nodes.

    Also known as: personal tumour-trained lymphocytes

06

What researchers measure

Primary outcomes

  1. Safety of pTTL administration, as determined by assessment of incidence and severity of adverse events (AE). Immunological AEs and AEs known to be associated with T cell therapies will be classified as AEs of special interest (AESI).

    To establish that pTTL can be administered to patients with advanced CRC without unacceptable toxicity. Adverse events (AEs) will be collected and assessed according to Common terminology criteria for AEs (CTCAE) v5.0. Special focus will be placed on immunological AEs and AEs known to be associated with T cell therapies, defined as AEs of special interest (AESI). AESI will include autoimmune reactions potentially resulting from off-target toxicity such as colitis, and immune-mediated reactions associated with immune cell activation, such as cytokine release syndrome (CRS).

    Time frame: Final evaluation 6 months after pTTL therapy

Secondary outcomes

  1. Objective response

    Measured using radiology (including CT, MR or other applicable examination) and assessed according to iRECIST

    Time frame: Final evaluation 6 months after pTTL therapy

  2. Time to treatment response

    The time between administration and documented objective response

    Time frame: Final evaluation 6 months after pTTL therapy

  3. Duration of treatment response

    The time from when an objective response is initially documented to the time of subsequent tumour progression.

    Time frame: Final evaluation 6 months after pTTL therapy

  4. Time to tumour progression

    The time to tumour progression after pTTL administration will be assessed using the iRECIST criteria and will take into account the time from inclusion in Part II of the trial until disease progression.

    Time frame: Final evaluation 6 months after pTTL therapy

  5. Kinetics of tumour progression/growth (compared to pre-treatment)

    This measurement will be based on iRECIST, and will use radiological examinations (including CT, MR or other applicable examination) before and after pTTL administration in an endeavour to evaluate whether the progression kinetics of the patient's cancer is affected by pTTL administration

    Time frame: Final evaluation 6 months after pTTL therapy

  6. Overall survival

    Defined as time from inclusion to death of any cause.

    Time frame: First evaluation at 6 months after pTTL therapy, with a final evaluation at the close of the study at a maximum of 5 years after pTTL administration.

  7. Progression-free survival

    Defined as time from inclusion to tumour progression or death of any cause.

    Time frame: First evaluation at 6 months after pTTL therapy, with a final evaluation at the close of the study at a maximum of 5 years after pTTL administration.

  8. Disease-specific survival

    Defined as time from inclusion to death of disease.

    Time frame: First evaluation at 6 months after pTTL therapy, with a final evaluation at the close of the study at a maximum of 5 years after pTTL administration.

Other outcomes

  1. Biomarker analysis for evaluation of pTTL persistence

    T cell receptor sequencing (TCRseq) will be used to characterise the pTTL product and to trace the identified pTTL clones in sequential peripheral blood samples post treatment.

    Time frame: First evaluation at 6 months after pTTL therapy, with a final evaluation at the close of the study at a maximum of 5 years after pTTL administration.

  2. Biomarker analysis for evaluation of pTTL tumour infiltration

    If feasible, pre- and post-treatment biopsies will be taken for histological assessment of T cell infiltration and characterisation of tumour-infiltrating T cells.

    Time frame: First evaluation at 6 months after pTTL therapy, with a final evaluation at the close of the study at a maximum of 5 years after pTTL administration.

  3. Biomarker analysis for evaluation of pTTL neoantigen specificity

    Functional T cell assays (including but not limited to flow cytometry and cytokine release assays) will be used to evaluate neoantigen-specific responses in the pTTL product and in peripheral blood T cells, reflecting the extent of neoantigen reactivity in the different samples.

    Time frame: First evaluation at 6 months after pTTL therapy, with a final evaluation at the close of the study at a maximum of 5 years after pTTL administration.

  4. Biomarker analysis for evaluation of pTTL neoantigen efficacy - serum tumour markers

    Serum tumour markers (the choice of markers will be made according to the patient's tumour characteristics) will be assessed as a biomarker of efficacy, as it reflects changes in tumour burden.

    Time frame: First evaluation at 6 months after pTTL therapy, with a final evaluation at the close of the study at a maximum of 5 years after pTTL administration.

  5. Biomarker analysis for evaluation of pTTL neoantigen efficacy - ctDNA

    Circulating tumour DNA (ctDNA) will be assessed as a biomarker of efficacy, as it reflects changes in tumour burden.

    Time frame: First evaluation at 6 months after pTTL therapy, with a final evaluation at the close of the study at a maximum of 5 years after pTTL administration.

  6. Biomarker analysis for evaluation of pTTL characteristics

    Analysis of the pTTL product and of post therapy peripheral blood samples will be performed to evaluate the functional status, differentiation and lineage-identity of T cells and other immune cells. This is an exploratory outcome measure, where a large set of phenotypical aspects will be assessed in order to understand which characteristics are important for pTTL efficacy and potentially also to side effects. Evaluations of the T cells are performed using assays including, but not limited to, flow cytometry and RNA sequencing, to characterize the T cells with regard to identity, differentiation and functions which could be relevant to the efficacy of pTTL.

    Time frame: First evaluation at 6 months after pTTL therapy, with a final evaluation at the close of the study at a maximum of 5 years after pTTL administration.

  7. Evaluation of the importance of neoantigen selection to clinical outcome.

    Data relevant for the correlation of neoantigen selection to clinical outcome will be stored and assessed. Aspects such as type of genetic alteration, variant allele frequency, RNA expression, and protein type and function will be considered and assessed in the context of clinical outcomes, signals of efficacy and biomarker evaluation. This is an exploratory outcome measure, and multiple assessments will be performed to better understand what neoantigen characteristics that could affect efficacy of pTTL.

    Time frame: First evaluation at 6 months after pTTL therapy, with a final evaluation at the close of the study at a maximum of 5 years after pTTL administration.

07

Study locations

2 sites
  • Medical Unit Cell therapy and Allogeneic Stem cell Transplantation (ME CAST), and the Center for Clinical Cancer studies - Phase 1 unit, Karolinska University Hospital
    Stockholm, Stockholm County 17176, Sweden
  • Unit for Colorectal Surgery, Dept. of Surgery, Västmanlands Sjukhus Västerås
    Västerås, Västerås 723 35, Sweden
08

References and documents

Publications

  • Tarfy A, Salmen A, Gafvelin G, Gronlund H, Chabok A, Nikberg M, Nilsson PJ, Carlsten M, Kordes M, Berglund S. A first-in-human, phase I/IIa trial of the T cell immunotherapy personalised tumour trained lymphocytes in patients with advanced colorectal cancer: Study protocol. PLoS One. 2026 Sep 18;21(9):e0351697. doi: 10.1371/journal.pone.0351697. eCollection 2026. PubMed 42758681 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2030, 93 months after the start.

Of 159 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 93 months is above that.

Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2027 → Dec 2030 and completion Jun 2032 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2023
First posted
Jun 18, 2023
StartActual
Mar 15, 2023
Primary completionEst.
Dec 2030was Dec 2027
CompletionEst.
Dec 2030was Jun 2032
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 28, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Sweden)
  • Medical Unit Cell therapy and Allogeneic Stem cell Transplantation (ME CAST), and the Center for Clinical Cancer studies - Phase 1 unit, Karolinska University Hospital · Stockholm, Sweden
  • Unit for Colorectal Surgery, Dept. of Surgery, Västmanlands Sjukhus Västerås · Västerås, Sweden
Show 2 removed
  • Medical Unit Cell therapy and Allogeneic Stem cell Transplantation (ME CAST), and the Center for Clinical Cancer studies - Phase 1 unit, Karolinska University Hospital · Stockholm, Sweden
  • Unit for Colorectal Surgery, Dept. of Surgery, Västmanlands Sjukhus Västerås · Västerås, Sweden
Oct 28, 2026
Primary completion
Dec 2027→Dec 2030
Oct 28, 2026
Study completion
Jun 2032→Dec 2030
Oct 28, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42758681 ↗
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Active, not recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42758681 ↗
    2 sites added, 2 sites removed
    Show 2 added (2 Sweden)
    • Medical Unit Cell therapy and Allogeneic Stem cell Transplantation (ME CAST), and the Center for Clinical Cancer studies - Phase 1 unit, Karolinska University Hospital · Stockholm, Sweden
    • Unit for Colorectal Surgery, Dept. of Surgery, Västmanlands Sjukhus Västerås · Västerås, Sweden
    Show 2 removed
    • Medical Unit Cell therapy and Allogeneic Stem cell Transplantation (ME CAST), and the Center for Clinical Cancer studies - Phase 1 unit, Karolinska University Hospital · Stockholm, Sweden
    • Unit for Colorectal Surgery, Dept. of Surgery, Västmanlands Sjukhus Västerås · Västerås, Sweden
    Primary completion Dec 2027→Dec 2030
    Study completion Jun 2032→Dec 2030
    + 4 other changes: index terms, verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05908643
Lead sponsor
Neogap Therapeutics AB
Collaborators
CTC Clinical Trial Consultants AB, Karolinska University Hospital, Region Västmanland, Vecura
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Mar 15, 2023
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 28, 2026

Study contacts

Maximilian Kordes, MD, PhD
principal investigator · Medical Unit Cell therapy and Allogeneic Stem cell Transplantation, Karolinska University Hospital
Abbas Chabok, MD, PhD
principal investigator · Unit for Colorectal Surgery, Dept. of Surgery, Västmanlands Sjukhus Västerås

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion